伊立替康肝动脉化疗栓塞联合5-Fu/CF静脉化疗治疗结直肠癌肝转移的临床观察

目的评价伊立替康介入栓塞联合5-Fu/CF静脉化疗治疗结直肠癌肝转移的疗效和毒性。方法结直肠癌肝转移患者行TACE术，伊立替康（CPT-11）加超液化碘油化疗栓塞，介入完成后即行5-Fu/CF静脉化疗，每3周重复。结果全组26例患者共接受了98个周期化疗，平均4个周期（3~6周期）。CR 2例（7.69%），PR 8例（30.77%），SD13例（50%），PD 3例（11.54%）；临床获益率88.46%（23/26）；中位疾病进展时间7.3月;中位生存期14.2月。最常见的毒副反应是中性粒细胞减少，消化道反应，多为Ⅰ～Ⅱ级。结论伊立替康肝动脉化疗栓塞联合CF/5-Fu静脉化疗治疗结直肠癌肝转移疗效肯定，毒性反应可以耐受。

Clinical Study of TACE with Irinotecan and Lipiodol Combining with Intravenous Chemo therapy of CF/5-Fu in Treatment of Hepatic Metastasis from Colorectal Cancer

Objective To evaluate the efficacy and toxicity of TACE using Irinotecan and lipiodol combining with intravenous CF/5-Fu in the treatment of hepatic metastasis from colorectal cancer. Methods Twenty six cases with hepatic metastasis from colorectal cancer were treated by the above mentioned method, every three weeks was a cycle. Results Two cases had complete response, eight cases had partial response,thirteen cases had stable disease and three cases with progressive disease. Gross efficiency rate was 38.46% and the stability rate was 50%.The clinical beneficial response rate was 88.46%.Median time to progression was 7.3 months and median overall survival time was 14.2 months. The common treatment related adverse events were neutropenia and delayed diarrhea. Toxic effect was light. Conclusion TACE using Irinotecan and Lipiodol combining with intravenous CF/5-Fu in the treatment of hepatic metastasis from colorectal cancer is an effective and well tolerated regimen.